Roche, GE Healthcare launch NAVIFY Tumor Board to enable personalised treatment decisions in cancer care

The new version of NAVIFY Tumor Board is initially available in the United States and Canada with additional markets to follow in the near future.

New Delhi: Roche recently announced the release of NAVIFY Tumor Board 2.0, the first collaboration product from our partnership with GE Healthcare. Incorporating medical image viewing and storage capabilities with other patient data, the product enables tumour boards - multi-disciplinary teams who determine treatment plans for cancer patients - to have a more comprehensive view of each patient in one place.

Bringing together patient medical records from various systems for review by tumour boards can be time-consuming and cumbersome. The integration of GE Healthcare's medical image viewer into NAVIFY Tumor Board 2.0 enables radiologists to upload their patient records to the same dashboard where patient files from other disciplines in the cancer care team are stored. Having complete patient diagnostic information in one location helps specialists use the limited time they have during tumour boards to review all relevant files quickly and align on the best possible treatment plan for each cancer patient.

Read Also: Roche gets USFDA nod for combo drug Venclexta, Gazyva to treat lymphocytic leukaemia

Commenting on the launch, Michael Heuer, CEO Roche Diagnostics said, "This new version of NAVIFY Tumor Board is the first product developed in partnership with GE Healthcare and demonstrates our shared vision of accelerating personalised healthcare."

"Our mutual focus is on delivering clinical decision support solutions that enable healthcare professionals to make faster, more confident decisions, allowing more personalized treatment based on truly integrated diagnostics, " Michael added.

"We are delighted to announce the first major milestone of our ongoing collaboration with Roche, as we work together to enable precision healthcare. Workflows around tumour boards can be inefficient, and we hope this single, holistic dashboard - including patient data and images - will enable oncology teams to align more quickly on the most optimal diagnosis and treatment plan for the benefit of each patient," said Tom McGuinness, President and CEO, GE Healthcare Imaging.

Read Also: Roche withdraws refiling of Premerger Notification, Report Form under the HSR Act

The partnership combines Roche expertise in advanced lab testing and the GE Healthcare leadership in medical imaging and monitoring to provide an ecosystem of workflow solutions and apps on an industry-first shared integrated diagnostics platform.

The companies are aiming to design products to enable seamless integration and analysis of comprehensive lab and medical imaging data, patient records, medical best practice, real-time monitoring and the latest research outcomes. Clinicians will then have confidence that they are making the best possible treatment decision for each patient.

The new version of NAVIFY Tumor Board is initially available in the United States and Canada with additional markets to follow in the near future.